Research Library

The top resource for free research, white papers, reports, case studies, magazines, and eBooks.

Share Your Content with Us
on for readers like you. LEARN MORE
Paying Attention
Request Your Free eBook Now:

"Paying Attention"

A look at how the proposed ruling on copay accumulators will impact more than just the bottom line for both pharma and patients

On June 17, 2020, the Centers for Medicare and Medicaid Services issued a proposed rule that, if finalized, would revise how manufacturer coupons are accounted for in best price calculations. As a copay program provider, TrialCard believes this will have a negative effect on a pharmaceutical manufacturer’s ability to deliver much-needed patient assistance for high-cost specialty medications, many of which do not have generic alternatives. Access this important eBook today for more insights.

An in-depth discussion with Rick Fry, SVP, commercial solutions, TrialCard; Peter Pitts, president and cofounder, Center for Medicine in the Public Interest; Bill Sarraille, partner, Sidley Austin; Carl Schmid, executive director, HIV + Hepatitis Policy Institute; Stacey Worthy, partner, DBCA Law and executive director, Aimed Alliance; and Jason Zemcik, senior director, product management, TrialCard addressed how brands and pharmaceutical manufacturers can navigate the challenges of the proposed rule.

  • Reducing the benefit amount of your copay offer to avoid being negatively exposed to best price reporting
  • Educating employer groups on the impact of copay accumulators beyond just financial savings tools including analyzing their effects on employee productivity and long-term healthcare costs
  • Designing healthcare programs to best address all of the complex issues of the proposed rule
  • Proactive steps that can be taken to mitigate potential effects of the proposed rule including working at the state level to combat it

Offered Free by: Trialcard
See All Resources from: Trialcard

Recommended for Professionals Like You: